Looks like XKEM is going to be making some SERIOUS progress here in the VERY near future!!!!
If you look at this (source below), XKEM will have to pay 16,600 to Alembic starting in July 2006 EVERY MONTH!
I don't know about you, but if my corporation had a 16K a month recurring revenue hanging in the wind... I would be busting my arse to complete the agreement and/or boost my stock high enough so I could throw them some shares to make the debt go away.
I think they will be making a wealth of press releases coming up in the near future to help boost their outward appearnence and drive up some "deals" before July rolls around.
Caption: Xechem agrees to repay Alembic in full the outstanding principal and interest remaining from the New Note as follows: $1,000,000 to be paid on or before January 31, 2006 (the "Initial Payment"), with the balance (the "Remaining Balance") due on or before December 31, 2006. Furthermore, for every month beginning July 2006, in which any portion of the New Note remains unpaid, Xechem shall pay to Alembic as additional consideration the sum of $16,600, for a total of up to $99,600.
A different company is also trying to push a sickle cell drug. They are only in thier initial testing on people though and XKEM has been testing theirs on humans for some time.
This other company is running at 8.35 up .40 cents!!!!
Go sickle cell research companies!!!! I LOVE drugs!
posted
March 3rd, 2006 Obasanjo to launch locally produced sickle cell drug
President Olusegun Obasanjo will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder. PATIENCE OGBE Abuja
The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN
The drug NIPRISAN (HEMOXIN(TM), which is at present, undergoing final stage of registration with NAFDAC is a phyto-pharmaceutical drug for the treatment of patients suffering from Sickle Cell Disease (SCD). SCD is an insidious and painful genetic blood disorder often resulting in death at an early age.
Science and Technology Minister, Turner Isoun who disclosed this in Abuja noted that location of the factory in Nigeria would further crash the price of sickle cell drugs in Nigeria.
Isoun stated that Niprisan (HEMOXIN(TM)) was a drug cocktail, with phyto-pharmaceutical composition of four traditional plants extracted in a proprietary process. The licensor of the technology is the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria.
Nigeria is said to have the highest sickle cell disease population in the world ranging from four to six million representing roughly three to five percent of the country's population.
Isoun spoke at the inaugural meeting of the Ministers’ Council for the National Biotechnology Development Agency (NABDA) where he also called on the government to involve more laboratories for the control and analysis of the bird flu menace.
On the situation of bio technology in Nigeria, he called on the stockholding agencies to ensure that Nigeria benefits from the judicious and safe use of modern biotechnology.
"Biotech is a gold mine and important to this nation. Almost every Nigerian is affected by the operations of biotech. To be able to achieve all these, we will require the concerted political will and a focused leadership drive. It is therefore the collective responsibility of all of us key stakeholders of modern biotechnology to join forces in realizing this vision.
It is my belief that this collective mission will not jeopardize our separate mandates but will promote the effective coordination of our effort towards achieving the same ultimate goal."
To achieve the nation’s targets in biotech, the Director General of the National Biotechnology Development Agency (NABDA), Bamidele Solomon called for the establishment of biotechnology development fund.
The fund, he stressed, could help the nation support competent researches and be ready to tackle problems like the bird flu.
He also disclosed that Nigeria in collaboration with Trinity Biotech of the Republic of Ireland will establish a facility at SHESTCO Abuja for the production of test kits for HIV/AIDS and other diseases like HB, malaria and so on.
He added that the Federal Government has approved the sum of $28 million as counterpart commitment for the project.
He also spoke of Nigeria’s collaboration with Shantha Biotechnics Limited of India for the establishment a facility for the production of Hepatitis B vaccine and other vaccines for related diseases like typhoid, polio, DTP and related ailments.
"Government approved the sum of N10 Million in the 2004 capital budget to support carrying out of a detailed feasibility study and fulfilling other MoU requirement."
Thanks Slippery!!!
-------------------- Buy Low. Sell High. Posts: 10754 | From: The Land Of The Giants | Registered: Feb 2005
| IP: Logged |
XetaPharm is a subsidiary of Xechem. The have a drug called Vida Pras that is a herb that is used to boost the immune system. It was mentioned in an article from 2001 at DrugTopics.com.
Some of their other drug names: Gugulon GinsengOnce GarlicOnce Co-Enzyme Q-10 Vida Pras
posted
FOR IMMEDIATE RELEASE Xechem Announces Launch of Nicosan™ (formerly "Niprisan") A Treatment for Sickle Cell Disease
NEW BRUNSWICK, NEW JERSEY, Feb. 3 -/E-Wire/-- Xechem International, Inc. (OTC BB: ZKEM) announced today that it anticipates the initial sales of NICOSAN™, its Sickle Cell Anemia Drug for distribution in Nigeria in late March or early April 2003, through its subsidiary ("Xechem Nigeria"). Xechem Pharmaceuticals Nigeria Limited is organized under the Companies and Allied Matters Act (1992) of the Federal Republic of Nigeria.
All manufacturing, marketing, distribution and sales of the product NICOSAN™ will take place through Xechem Nigeria at this time. This will place Xechem in a unique position to take full advantage of Nigeria's well-known biodiversity, which is expected to yield many new, important drugs and other phyto-pharmaceutical products.
On July 18, 2002, Xechem International, Inc. signed an exclusive worldwide license for the manufacturing, marketing, distribution and sales of NIPRISAN™ from the National Institute of Pharmaceutical Research and Development ("NIPRD"), government of Nigeria, for the treatment of Sickle Cell Disease ("SCD"). NICOSAN™ is Xechem's name for the non-toxic phyto-pharmaceutical product formerly named NIPRISAN™. Xechem is currently in the process of completing for submission of an Investigational New Drug Application ("IND") for this product to the United States Food and Drug Administration ("FDA"). To date, there has been no successful non-toxic drug developed for the treatment of SCD.
According to Xechem's President and CEO, Dr. Ramesh C. Pandey, "Xechem is in position to take advantage of the extraordinary biodiversity of Nigeria and the African continent. Our ability to develop life saving and life extending medicinal products from natural sources is evident in our history as a company as well as our commitment to work hand in hand with the government of Nigeria. Currently over 25% of the Nigerian population is a carrier of SCD and over 6.4 million Nigerians, 5% of the population are afflicted with this horribly painful disease."
Xechem International, Inc., headquartered in New Brunswick, N.J., with subsidiary companies in the USA, India, Nigeria and joint venture partners in both Hong Kong and the Peoples Republic of China, is a biopharmaceutical engaged in the research, development and production of generic and proprietary drugs from natural sources. The company specializes in the development of niche-generic, difficult to replicate, anti-cancer, antiviral compounds, including Human Immuno-deficiency Virus ("HIV") and anti-fungal compounds. Xechem is also engaged in the research and development of several novel anti-infectives showing strong and selective efficacy against an array of antibiotic resistant bacterias, including Helicobacter pylori (H. pylori), Vancomycin resistant Enterococcus faecalis (VREF), Methicillin resistant Staphylococcus aureus (MRSA), and other antibiotic resistant Staphylococcus aureus and Candida albicans. The Company also screens extracts and pure compounds from various parts of the world for their therapeutic use.
XetaPharm (another U.S. subsidiary) develops quality controlled nutritional products such as GinkgoOnce®, GinsengOnce®, GarlicOnce®, Gugulon™, VIDA PRAS™ and numerous other nutraceutical products, which are under development.
This and past press releases of Xechem International, Inc. are available at Xechem's web site at www.xechem.com.
This news release may contain certain forward-looking statements relating to Xechem's future business performance within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.
-------------------- Just looking to have .30 cents more than yesterday...or $$3,000,000...When opportunity knocks, TAKE IT! Posts: 194 | Registered: Mar 2006
| IP: Logged |
posted
Sold 200k at .027 yesterday, hoping for a return to .02 before getting back in. Actually looking to pick up a few shares for a long term hold. Haven't been able to find anything negative about this company, do I have blinders on, or does this look good for the long haul?
posted
If XKEM goes green today, I may just not be able to sell this sucker, we'll see what happens. Today's shake was a little harder than yesterday's.
1 MM left at .023 on the ask.
.0247 Resistance.
-------------------- Buy Low. Sell High. Posts: 10754 | From: The Land Of The Giants | Registered: Feb 2005
| IP: Logged |